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Abstract
Background
In resource-limited settings holding regimens, such as lamivudine monotherapy (LM), are
used to manage HIV-positive children failing combination antiretroviral therapy (cART) to
mitigate the risk of drug resistance developing, whilst adherence barriers are addressed or
when access to second- or third-line regimens is restricted. We aimed to investigate charac-
teristics of children placed on LM and their outcomes.
Methods
We describe the characteristics of children (age <16 years at cART start) from 5 IeDEA-SA
cohorts with a record of LM during their treatment history. Among those on LM for >90 days
we describe their immunologic outcomes on LM and their immunologic and virologic out-
comes after resuming cART.
Findings
We included 228 children in our study. At LM start their median age was 12.0 years (IQR
7.3–14.6), duration on cART was 3.6 years (IQR 2.0–5.9) and median CD4 count was 605.5
cells/μL (IQR 427–901). Whilst 110 (48%) had no prior protease inhibitor (PI)-exposure, of
the 69 with recorded PI-exposure, 9 (13%) patients had documented resistance to all PIs.
After 6 months on LM, 70% (94/135) experienced a drop in CD4, with a predicted average
CD4 decline of 46.5 cells/μL (95% CI 37.7–55.4). Whilst on LM, 46% experienced a drop in
CD4 to <500 cells/μL, 18 (8%) experienced WHO stage 3 or 4 events, and 3 children died.
On resumption of cART the average gain in CD4 was 15.65 cells/uL per month and 66.6%
(95% CI 59.3–73.7) achieved viral suppression (viral load <1000) at 6 months after resum-
ing cART.
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Interpretation
Most patients experienced immune decline on LM. Its use should be avoided in those with
low CD4 counts, but restricted use may be necessary when treatment options are limited.
Managing children with virologic failure will continue to be challenging until more treatment
options and better adherence strategies are available.
Introduction
Treatment failure among HIV-positive children is a growing concern.[1] In resource-limited
settings, where access to second- or third-line combination antiretroviral therapy (cART) for
HIV-positive children is frequently restricted, managing virologic failure is especially challeng-
ing.[2] Children and adolescents face a number of adherence barriers, and drug formulations
are often unpalatable with large pill burdens.[3–5] Switching children with virologic failure,
who have suspected or proven poor adherence, to a new regimen runs the risk of increasing
resistant mutations, thus limiting future treatment options. The South African national guide-
lines recommend holding strategies for those with ongoing adherence challenges.[6]
Lamivudine monotherapy (LM) is one such holding regimen. This commonly used holding
strategy reduces the pill burden to patients and allows time for adherence barriers to be
addressed. It is also used whilst awaiting access to second- or third-line regimens, not always
readily available. Lamivudine has a low genetic barrier to resistance and most patients with
virologic failure develop the M184V mutation.[7] LM retains this HIV variant which has
reduced viral fitness and may therefore slow immune decline whilst ensuring new drug resis-
tance does not develop.[8–13]
There are few studies of the use and effectiveness of LM in children, despite it being recom-
mended in national guidelines. Three small South African studies found that CD4 count
declined slowly on LM and those with higher CD4s did not experience significant declines.
[14–17] We aimed to describe the characteristics and outcomes of children placed on LM, to
provide further evidence to guide the appropriate use of this treatment strategy, using data
from the International epidemiologic Database to Evaluate AIDS (IeDEA) Southern Africa
collaboration, which combines data across multiple sites across Southern Africa.
Materials and methods
Study design, setting and population
Data were collected prospectively from five IeDEA-SA cohorts in South Africa. IeDEA is a
multi-regional HIV cohort collaboration, which has been previously described.[18] The
requirement for informed consent has been waived as only anonymized data already collected
as part of routine monitoring is contributed to the collaborative dataset. All sites have local
institutional ethics approval to contribute data to IeDEA-SA analyses as follows: University of
Cape Town (Khayelitsha ART Programme, Red Cross Children’s Hospital); University of Wit-
watersrand (Harriet Shezi Clinic, Rahima Moosa Mother and Child Hospital); and University
of Stellenbosch (Tygerberg Academic Hospital).
We included data from children (<16 years) initiating cART after 2004, with a record of
being on LM at some point in their treatment history. Outcomes and more detailed analysis
was performed on patients who received LM for more than 90 days. Database closure ranged
from October 2015 to February 2016 across sites.
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Treatment regimens
All sites made use of routine viral load (VL) monitoring and are part of the South African
national ART program. The following treatment guidelines were in place during the study
period: Before 2007 the recommended first-line regimen was stavudine, lamivudine and either
efavirenz, or, for those starting treatment younger than three years of age, lopinavir/ritonavir
(LPV/r). For those with tuberculosis or starting treatment under the age of six months, LPV/r
was replaced with ritonavir alone.[19] After 2007, LPV/r was recommended for all children
under the age of three years, with ritonavir super-boosting when co-treating for tuberculosis.
[20, 21] From 2010, abacavir replaced stavudine in the recommended first-line regimen.
The recommended second-line regimen prior to 2010 was to change at least one of the
nucleoside reverse transcriptase inhibitors (NRTIs) and replace efavirenz with LPV/r (if on
efavirenz-based first-line), or switch to non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based second-line for those on protease-inhibitor (PI) based first-line.[19] The rec-
ommendation of switching to NNRTI-based second-line was replaced in the 2010 guidelines:
for children failing LPV/r-based regimens specialist referral was recommended. For those who
have failed PI-based cART, access to third-line or salvage regimens is through a national com-
mittee who reviews each patient’s treatment history individually. These regimens typically
include drugs that may be difficult to access, such as new generation PIs like darunavir, or inte-
grase inhibitors like raltegravir. Resistance testing was not routinely available during the study
period.
Key variables
Demographic, laboratory and clinical data at cART start and at the start of LM included age,
gender, CD4 count and CD4%, age-adjusted weight and height z-scores, WHO stage, immune
status according to WHO 2006 criteria for immunosuppression,[22] and first-line cART regi-
men. We considered additional characteristics at the start of LM, specifically nadir CD4% and
VL prior to LM start, history of treatment interruption (defined as discontinuing all antiretro-
virals for at least 7 days), and resistance profile where available. We also examined clinical data
of patients whilst on LM including death, clinical disease and WHO stage 3 or 4 events. We
considered disease events to be any opportunistic infection or incident HIV-associated diag-
noses recorded in our dataset.
Analysis
In this analysis, we described the characteristics of patients receiving LM summarizing contin-
uous and categorical variables using medians and interquartile ranges, and proportions respec-
tively. For patients with multiple episodes of LM, the first episode of at least 90 days was used.
To better understand immunologic outcomes we explored mean changes in CD4 count whilst
on LM, as well as immune decline, which we defined as either a drop in CD4 below 500 cells/
μL for those starting LM with CD4 above 500 cells/μL, or for those starting LM with CD4
count of 500 or below, a drop in CD4 of more than 10%. We used Kaplan-Meier estimates for
children on LM for at least 90 days and with at least 6 months of follow-up on LM to predict
probability of immune decline whilst on LM. Survival was calculated from the date of LM start
until either the date that immune decline was recorded, death, or censoring at the last clinical
visit recorded before database closure. Predictors of immune decline whilst on LM were deter-
mined using Cox-proportional hazards models adjusting for age at cART start, characteristics
prior to LM start including treatment interruption, nadir CD4 count and type of cART regi-
men, as well as duration on LM. To account for the non-independence of repeated CD4 mea-
sures taken for each patient, we used a linear mixed-effects regression models to determine the
Lamivudine monotherapy in children
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mean change in absolute CD4 count at 6 months on LM for patients with different characteris-
tics at LM start. We also explored the immunologic and virologic outcomes for patients who
resumed cART and had at least one subsequent CD4 count or VL. Kaplan-Meier estimates
were used to predict the probability of virologic suppression (VL<1000) for those who
resumed cART after LM. We used Cox-proportional hazards models to determine predictors
of virologic suppression after cART resumption adjusting for age at LM start and current regi-
men after resuming cART. To explore the immunologic changes after cART resumption we
calculated the CD4 slope for each child, as the difference between the CD4 at resumption of
cART (up to 90 days prior and 7 days post cART resumption) and the first CD4 count taken
within a year of cART resumption, divided by the time in months between these two measure-
ments. We used linear regression to explore associations with change in CD4 after cART
resumption adjusting for CD4 at cART resumption (> = 500 or <500), age at cART resump-
tion and exposure to PI-based cART prior to LM. For multivariate models we included a num-
ber of variables relating to characteristics at cART start (age, immune suppression), at LM
start (time on cART, time with virologic failure, most recent VL, most recent CD4 count,
recorded PI resistance, history of treatment interruption, cART regimen, nadir CD4 count)
and whilst on LM (duration of LM, experiencing an OI) a priori. For models relating to char-
acteristics after cART resumption after LM we included age at LM start, current regimen after
resuming cART, duration on LM, treatment interruption prior to LM, nadir CD4, CD4 at
cART resumption, age at cART resumption, exposure to PI-based cART prior to LM. Final
models were built by sequentially excluding variables through backwards selection using p-val-
ues. Statistical analysis was performed using Stata version 15 (STATA Corporation, College
Station, TX).
Results
Characteristics of patients at ART and LM start
In total, 228 patients (132, 58% male) with a history of being on LM were included in the
study. At cART start, median age was 7.4 years (IQR 3.2–10.0), median CD4 count was 348
cells/μL (IQR 190–616), median CD4% was 12.7% (IQR 7.6–18.0), and 118 (52%) were
immune-suppressed. Most patients were initiated on efavirenz-based first-line regimens
(70%), with 57 (25%) on PI-based first-line (Table 1).
At LM start the median age was 12.0 years (IQR 7.3–14.6) and patients had been on cART
for a median of 3.6 years (IQR 2.0–5.9), with median CD4 and CD4% of 605.5 cells/μL (IQR
427–901) and 22.2% (16.2–28.2), respectively; median VL was 4.2 log10 (IQR 3.7–4.7). Median
time with unsuppressed VL, calculated as the total time between the first consecutive unsup-
pressed VL measurement and the date of LM start, was 421.5 days (IQR 234.5–794), with a
median of 4 (IQR 2–5) unsuppressed VL measurements. Time with unsuppressed VL prior to
LM has decreased in more recent years: among those with at least 2 years of follow-up follow-
ing their first consecutive unsuppressed VL and those starting LM within 2 years of their first
consecutive unsuppressed VL, the median time with unsuppressed VL declined (2002–2005:
371 days (IQR 259–519), 2006–2009: 285 days (IQR 151–472), 2010–2014: 280 days (IQR 201–
425)). Prior to LM start, 110 (48%) were on efavirenz-based first-line regimens, whilst 108
(47%) had had prior exposure to PI-based regimens, one patient was on a third-line regimen,
two had been on other holding regimens, and seven had unknown treatment history.
Prior to initiating LM, 116 (51%) had undergone resistance testing. Among those tested,
107 (92%) patients had resistance to lamivudine with the majority having high level resistance
(96%, n = 103). Over half of patients had no PI resistance (72, 62%), whilst 10 (9%) were resis-
tant to all PI’s.
Lamivudine monotherapy in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0205455 October 11, 2018 4 / 12
Of 69 patients with recorded PI-exposure prior to LM and a resistance test, 38 (55%) had
no PI resistance, 10 (15%) were resistant to only nelfinavir, 12 (17%) were resistant to some
PIs and 9 (13%) were resistant to all PIs.
Outcomes on LM
At study closure the median duration on LM was 309 days (IQR 94.5–644), and 174 (76%)
children were on LM for more than 90 days. Four patients had been on LM on multiple occa-
sions between periods of receiving cART.
Three patients died whilst on LM, although details on cause of death were not available. All
had a CD4 at LM start >500 cells/μL and had previously been on PI-based cART (2 after first-
line PI, 1 after second-line PI). Time on LM for the 3 patients ranged from less than 6 months
to over 18 months, one patient dropped to a CD4<50 whilst on LM. In total, there were 114
new disease events among 53 patients whilst on LM. The median time to first disease event
was 94.5 days (IQR 45–359). There were 18 (8%) patients who experienced 26 WHO stage 3 or
4 event whilst on LM, the most common being extra pulmonary tuberculosis (5), recurrent
bacterial pneumonia (4), oral candidiasis (3), chronic HIV-associated lung disease (3), and
acute necrotising ulcerative stomatitis, gingivitis or periodontitis (3).
Table 1. Characteristics of children at cART start and at start of lamivudine monotherapy (LM) (n = 228).
Median (IQR) or N(%)
At cART start At LM start
Age in years 7.4 (3.2, 10.0) 12 (7.3, 14.6)
CD4 count, n 348 (190, 616), 163 605.5 (427, 901), 218
CD4% 12.7 (7.6, 18.0), 160 22.2 (16.2, 28.2), 217
Immunosuppression1 118 (72%), 165 42 (20%), 207
Weight-for-age Z-score -1.8 (-2.7, -0.9), 136 -0.8 (-1.8, -0.4), 217
Height-for-age Z-score -2.4 (-3.3, -1.5), 163 -1.9 (-2.7, -1.0), 215
cART regimen NNRTI-based firstline 165 (72%) 110 (48%)
NNRTI-based secondline 13 (6%)
PI-based firstline 57 (25%) 41 (18%)
PI-based secondline 52 (23%)
Unknown 3 (1%) 21 (9%)
Non-cART 2 (1%)
Other non-standard 1 (0%) 2 (1%)
Other holding regimen 2 (1%)
Thirdline 1 (0%)
WHO stage at cART start Stage 3 or 4 122 (54%)
Unknown 85 (37%)
Year of cART Start 2002–2005 51 (22%)
2006–2009 110 (48%)
2010–2014 67 (29%)
Duration (years) on cART at LM start 3.6 (2.0, 5.9)
CD4<500 at LM start 73 (33%)
Nadir CD4 at LM start, n 330 (176, 515), 218
Log10 Viral Load at LM start, n 4.2 (3.7, 4.7), 217
Time with unsuppressed VL prior to LM (>400) 421.5 (234.5, 794), 217
Treatment interruption prior to LM 21 (9%)
1 According to WHO 2006 criteria for immunosuppression
https://doi.org/10.1371/journal.pone.0205455.t001
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At study closure, out of all 228 children, 167 patients had been switched from LM, 149 of
whom resumed cART. The majority, 135, were switched to or resumed PI-based regimens (84
switched, 47 resumed, and 4 had unknown treatment history), and 12 switched to or resumed
NNRTI-based regimens (7 resumed first-line, 1 resumed second-line, 3 were switched to sec-
ond-line, 1 unknown). One patient was switched to a third-line regimen, after having been on
PI-based second-line prior to LM, and one patient was switched to a non-standard cART regi-
men. Among the 18 patients not resuming cART, 4 were switched to other holding regimens
(all containing 2 NRTIs only), and 14 discontinued all treatment. We did not have data on the
reasons for treatment discontinuation, and the decision to stop all treatment may have been
planned and recommended by a clinician, or the decision of the patient.
Immune decline on LM
In total 147 patients were on LM for more than 90 days, had a recorded CD4 count at LM
start, and at least one subsequent CD4 count measured whilst receiving LM. The median time
from the CD4 count at LM start to the last CD4 on LM was 413 days (IQR 231–752). On aver-
age CD4 count measurements were taken every 132 days or every 4.3 months whilst on LM,
and the median time between CD4 measurements on LM was 112 days (IQR 91–158). The
median CD4 decline, from CD4 at LM start to the last recorded CD4 count on LM, was 148
cells/μL (IQR 28–414), 115 (78%) experienced a drop in CD4�10%, and among the 112 with
CD4�500 cells/μL at LM start 46% experienced a drop in CD4 to<500 cells/μL whilst on LM.
Results from our mixed effects model predicted an average CD4 decline at 6 months on LM
of 46.5 cells/μL (95% CI 37.7–55.4) from a mean CD4 of 708.4 to a mean of 661.9 cells/μL
(95% CI 601.8–721.9). CD4 count at LM start influenced immune decline on LM. The pre-
dicted average decline in CD4 at 6 months on LM for those with CD4 <500 was 21.5 cells/μL
(95% CI 9.7–33.2) to a mean CD4 of 306.8 cells/μL (276.2–337.5). For those with CD4�500 at
LM start, the predicted decline at 6 months was 55.5 cells/μL (95%CI 47.4–63.6), to a mean
CD4 of 752.3 cells/μL (95% CI 704.4–800.2). To illustrate the difference in CD4 decline for
patients of different characteristics, we estimated the average CD4 count at 6 months on LM
for patient of varying age, duration on cART, nadir CD4 and CD4 at LM start. These results
are summarized in Table 2.
According to our definition, 76 (52%) patients experienced immune decline on LM, with
an estimated probability of immune decline after 6 months on LM of 22.2% (95% CI 16.6%-
Table 2. Estimated CD4 count decline (95% confidence intervals) at 6 months on lamivudine monotherapy (LM) for children with specific age, duration on cART,
nadir CD4 and CD4 count at LM start (n = 135)�.
Age at LM start (years) Duration on cART prior to LM (years) Nadir CD4 CD4 at LM start = 1000 CD4 at LM start = 500
10 2 100 581.64 (403.99, 759.29) 329.11 (207.84, 450.39)
500 489.05 (326.04, 652.06) 236.53 (107.91, 365.14)
6 100 497.29 (330.69, 663.90) 244.77 (129.58, 359.95)
500 404.71 (249.26, 560.16) 152.18 (23.75, 280.62)
15 2 100 652.59 (437.81, 867.36) 400.06 (233.17, 566.95)
500 560.00 (354.73, 765.28) 307.48 (132.31, 482.64)
6 100 568.24 (369.97, 766.52) 315.72 (162.76, 468.68)
500 475.66 (284.04, 667.28) 223.14 (56.94, 389.34)
�This table provides the estimates for the decline in CD4 count after 6 months on LM for children of specific characteristics. Eg A child aged 10 years at the start of LM,
on cART for 2 years prior to LM with a nadir CD4 of 100 and a CD4 at LM start of 1000 will have experienced a drop in CD4 count of 581.6 cells/uL after 6 months on
LM
https://doi.org/10.1371/journal.pone.0205455.t002
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29.3%). Predictors of immune decline are summarized in Table 3. Older age was associated
with increased risk of immune decline; those over 9 years old had a four-fold increase in risk
compare to those under 2 years (aOR 4.2, 95% CI 2.2–8.3). Those on third-line or NNRTI-
based second-line were also at increased risk of immune decline compared to those on
NNRTI-based first-line prior to LM start (aOR 3.43, 95% CI 1.6–7.6). Treatment interruption
prior to LM, and lower nadir CD4 count were also associated with immune decline as was
shorter time on LM, likely because of switch from LM in those with immune decline or clinical
deterioration.
Outcomes after resuming cART
Table 4 summarizes the characteristics of patients resuming cART after LM among those on
LM for at least 90 days, at three time points: at LM start, on resumption of cART and 6 months
thereafter. Median CD4 count returned to pre-LM levels and VL was reduced. Results from
our regression analysis estimate a median CD4 slope of 15.65 cells/uL per month (IQR 1.52,
45.54). Given the small sample size we failed to demonstrate statistically significant associa-
tions with change in CD4, but those with CD4�500 cells/μl on resumption of cART tended to
have smaller increases in CD4 post cART resumption compared to those with CD4 <500
cells/μl (mean change 15.53 vs 36.02 per month).
Among the 103 patients resuming cART after at least 90 days on LM, 62% (64) achieved
virologic suppression after resuming cART, with estimated probability of VL suppression by 6
months after cART resumption of 66.6% (95% CI 59.3–73.7). In adjusted analysis, those on PI-
based cART were more likely to suppress compared to those resuming NNRTI-based cART
(aOR 1.9, 95% CI 1.3–2.8). Age was associated with VL suppression, with those 5 years or
younger (aOR 2.1 (95% CI 1.6–2.7), those 5 to 10 years of age (aOR 1.9 (95% CI 1.5–2.3) and
those aged 10 to 13 years (aOR 1.1 (95% CI 0.8–1.3) more likely to suppress compare to those
Table 3. Univariate and multivariable associations with a decline in CD4 of more than 10% from lamivudine monotherapy (LM) start OR drop in CD4 count below
500 in those with CD4>500 at LM start, stratified by site.
Characteristic at ART or LM start Unadjusted HR (95% CI), n = 157 p Adjusted HR (95% CI), n = 157 p
Age in years at ART start <2 1 <0.001� 1.00 0.0007�
2–6 2.24 (1.29, 3.91) 2.27 (1.16, 4.45)
6–9 3.08 (1.78, 5.35) 2.78 (1.34, 5.77)
>9 4.92 (2.95, 8.21) 4.15 (2.17, 8.34)
Complete treatment interruption prior to LM 1.39 (0.92, 2.10) 0.12 3.69 (1.78, 7.69) <0.001
Nadir CD4 prior to LM start > = 500 1 <0.001� 1.00 0.0054�
> = 350 - <500 2.07 (1.29, 3.35) 1.95 (1.14, 3.34)
> = 200 - <350 2.42 (1.54, 3.80) 2.30 (1.36, 3.90)
<200 3.45 (2.19, 5.42) 2.40 (1.42, 4.07)
Time on LM 90 days to 6 months 1 <0.001� 1.00 0.0041�
6 months—1 year 0.61 (0.28, 1.33) 0.53 (0.23, 1.24)
1–2 years 0.46 (0.21, 1.00) 0.47 (0.20, 1.08)
> 2 years 0.18 (0.08, 0.41) 0.23 (0.09, 0.56)
Regimen Prior to LM start NNRTI-based first-line 1 - 1.00
PI-based first or second-line 0.74 (0.52, 1.04) 0.08 1.24 (0.83, 1.87) 0.294
Third line or NNRTI-based second-line 0.79 (0.43, 1.46) 0.46 3.43 (1.55, 7.60) 0.002
Other / Unknown 1.23 (0.65, 2.34) 0.53 2.37 (1.13, 4.96) 0.022
�Derived from Wald’s test
https://doi.org/10.1371/journal.pone.0205455.t003
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older than 13 years. Regimen prior to LM was not associated with virologic suppression after
resumption of cART and was not included in the final model.
Among patients on PI-based regimens prior to LM, on resumption of PI-based cART 21/36
(58%) achieved VL suppression. Among the 46 patients on NNRTI-based first-line prior to
LM, a third (2/6) patients suppressed on NNRTI-based regimens after resuming cART, while
31/40 (78%) suppressed on PI-based cART.
Discussion
The majority of children placed on LM experienced declines in CD4, 8% experienced WHO
stage 3 or 4 events, and 3 children died. Those with higher CD4 count at LM start, lower nadir
CD4 and older age experienced bigger absolute declines in CD4 count. Our composite out-
come of immune decline (either a drop in CD4 below 500 cells/μL for those starting LM with
CD4 above 500 cells/μL, or for those starting LM with CD4 count of 500 or below, a drop in
CD4 of more than 10%) was experienced by roughly half of patients. Predictors of immune
decline were lower nadir CD4 count, and having a history of treatment interruption. After
resuming cART, the majority of patients achieved virologic suppression and some immune
recovery. Adolescents and those on NNRTI-based cART were less likely to achieve virologic
suppression on resumption of cART.
Most children placed on LM had failed to suppress virologically for over a year. Time with
unsuppressed VL prior to LM has decreased in more recent years suggesting a trend to earlier
adoption of this strategy. About half our population had limited treatment options and were
placed on LM after exposure to PI-based regimens, with 10 children having documented
Table 4. Characteristics of patients who resumed cART after>90 days on lamivudine monotherapy (LM), n = 103.
LM start cART resumption 6 months after cART resumption
Age in years� 12.01 (8.19, 14.08) 13.55 (9.60, 15.51) 14.01 (10.06, 15.81), n = 88
< = 5 14 (14%) 4 (4%) 4 (5%)
>5 - < = 10 20 (19%) 24 (23%) 18 (20%)
>10 - < = 15 50 (49%) 46 (45%) 37 (42%)
>15 19 (18%) 29 (28%) 29 (33%)
CD4 count (cells/μl)� 547 (368.5, 827.5), n = 88 357.5 (270, 575), n = 64 552 (310, 796), n = 74
<200 2 (2%) 10 (16%) 7 (9%)
> = 200–350 14 (16%) 20 (31%) 15 (20%)
> = 350–500 22 (25%) 17 (27%) 10 (14%)
> = 500 50 (57%) 17 (27%) 42 (57%)
log10 VL (copies/ml)
� 4.18 (3.70, 4.62), n = 90 4.55 (4.01, 5.16), n = 30 2.81 (1.88, 4.36), n = 73
VL<1000 6 (7%) 3 (10%) 40 (55%)
Regimen after LM
First-line NNRTI 52 (50%) 7 (7%) 6 (7%)
Second-line NNRTI 4 (4%) 4 (4%) 4 (5%)
First- or second-line PI 42 (41%) 89 (86%) 69 (78%)
Third-line 0 (0%) 2 (2%) 4 (5%)
Other cART 1 (1%) 1 (1%) 1 (1%)
Non-cART 1 (1%) 0 (0%) 3 (3%)
Unknown 3 (3%) 0 (0%) 0 (0%)
Discontinued all cART 0 (0%) 0 (0%) 1 (1%)
�Median (IQR), n = 103 unless otherwise indicated
https://doi.org/10.1371/journal.pone.0205455.t004
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resistance to all PIs. The other half of children placed on LM had only had exposure to
NNRTI-based first-line regimens and were placed on this strategy instead of switching directly
to PI-based second-line. After LM few of these children resumed NNRTI-based cART and
very few managed to suppress on this regimen. The majority resumed PI-based regimens and
had good virologic outcomes. For these children being on LM delayed the initiation of second-
line whilst risking further immune decline, although it is possible that barriers to adherence
were addressed during this time so that adherence was optimized by the time second-line was
started.
This study represents the largest cohort of children on LM, providing the most evidence on
the use of this strategy. We explored outcomes of patients on resumption of cART following
LM; only one US-based study of 36 patients has reported on similar outcomes.[23] Like all pre-
vious reports on LM outcomes, our observational study on immune decline on LM is subject
to confounding by indication. Those with clinical or immunological deterioration on LM may
be more likely to resume cART sooner, whilst those who are awaiting third-line and have no
option but to remain on LM, may experience larger CD4 declines and longer duration on LM.
This is shown in our results which indicate that those with shorter duration on LM and those
on third-line or requiring salvage regimens were at higher risk of immune decline.
We had no data on adherence, and therefore could not directly assess the effect of LM as a
strategy to improve adherence, or determine how much adherence influenced immunologic
outcomes on LM or outcomes on resumption of cART. We did not have data on the reason
for starting the patient on LM, and could only infer from the patient’s treatment history. Resis-
tance testing was not available for all patients. VL monitoring is not routinely performed for
those on non-supressive regimens like LM, so we could not assess the virologic consequences
of this strategy.
Our study had a larger and older study population than those previously published, but our
results are largely in agreement. Linder et al reported generally larger immune declines, but
children in their study started LM with lower CD4 counts, and had longer durations on LM
(mean duration of over 2 years compared to our median of under 1 year).[15] A similar pro-
portion of patients experienced stage 3 or 4 clinical events, but in our study 3 patients died
whilst on LM, although we had no details on the cause. No other study has reported deaths
while on this strategy. Our results are not representative of children <3 years of age, and it is
perhaps advisable to avoid LM in young children given the lack of data in this age group.
There has been some attempt to prospectively compare outcomes of holding regimens like
LM, with other strategies to manage virologic failure in children. The IMPAACT P1094 study
enrolled children failing non-NNRTI-based cART, and aimed to compare outcomes of those
randomized to continue with failing cART versus changing to a holding regimen of lamivu-
dine or emtricitabine monotherapy. The study was discontinued due to lack of enrolment, but
results from the small study population indicate greater immune decline for those on holding
regimens.[24] Fairlie et al report on a US-based cohort of children comparing strategies for
managing children with virologic failure, including holding regimens such as LM, but were
unable to reach conclusions about holding regimens as compared to switching to a new regi-
men, continuing on a failing regimen or discontinuing all cART, due to sample size con-
straints.[25] An observational study of children from a US-based cohort who interrupted
treatment, either by discontinuing all cART or by being placed on LM, found better immune
rebound after restarting cART among those on LM compared to restart after complete treat-
ment interruption.[23]
This study provides useful evidence on the outcomes of children on LM and after resuming
cART, providing guidance on which patients are at greater risk of immune deterioration on
LM. This strategy should be avoided among children with low CD4 counts, and patients on
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LM require careful monitoring. Half of our study population were failing PI-based regimens
and had limited treatment options available to them. As more HIV-positive children are
started on PI-based cART due to earlier HIV diagnosis, it is likely that an increasing number
of children will experience virological failure on PI-based cART. As long as treatment options
for children remain scarce, and the risk of poor adherence and resistance continues, the use of
holding regimens like LM, could increase as the numbers of children failing treatment grow.
There is an urgent need for evidence to inform the optimal management of children with viro-
logical failure, as well as to inform second- and third-line options for children in resource-lim-
ited settings.[26] As new antiretrovirals such as the integrase inhibitors dolutegravir and
raltegravir become more widely accessible, giving children more treatment options, the use if
LM as an initial strategy to manage virologic failure in children should be reconsidered. Our
findings that adolescents were less likely to achieve virologic suppression on resumption of
cART, highlights the challenge of managing treatment failure and maintaining life-long adher-
ence in this vulnerable population. Effective adherence support strategies are urgently needed
as the number of adolescents on cART continues to grow.
To understand how best to manage virologic failure in children and adolescents, compari-
son between switching patients directly to second-line, keeping them on their failing regimen
or discontinuing all treatment is needed. This will allow a better understanding of the benefits
and potential risks of using holding regimens like LM.
Conclusion
In conclusion, most patients experienced immune decline on LM, and its use should be
avoided in those with low CD4 count. LM may be a useful strategy in the management of
patients with virologic failure and poor adherence when treatment options are limited, but
close clinical and immunological monitoring is required. Managing children with virologic
failure will continue to be challenging until more treatment options and better adherence strat-
egies are available.
Acknowledgments
Research reported in this publication was supported by the National Institute Of Allergy And
Infectious Diseases of the National Institutes of Health under Award Number U01AI069924.
The content is solely the responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health. The authors would like to acknowledge all
patients, caregivers, and data managers involved in IeDEA-SA cohorts.
Principal investigators:
Mary-Ann Davies, Centre for Infectious Disease Epidemiology and Research, School of
Public Health and Family Medicine, University of Cape Town, South Africa, mary-ann.davie-
s@uct.ac.za
Matthias Egger Institute of Social and Preventive Medicine, University of Bern, Switzer-
land, matthias.egger@ispm.unibe.ch
Site investigators and cohorts:
Gary Maartens, Aid for AIDS, South Africa; Michael Vinikoor, Centre for Infectious
Disease
Research in Zambia (CIDRZ), Zambia; Monique van Lettow, Dignitas, Malawi; Robin
Wood,
Gugulethu ART Programme, South Africa; Nosisa Sipambo, Harriet Shezi Clinic, South
Africa; Frank Tanser, Africa Centre for Health & Population Studies (Hlabisa), South
Africa;
Lamivudine monotherapy in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0205455 October 11, 2018 10 / 12
Andrew Boulle, Khayelitsha ART Programme, South Africa; Geoffrey Fatti, Kheth’Impilo,
South Africa; Sam Phiri, Lighthouse Clinic, Malawi; Cleophas Chimbetete, Newlands
Clinic,
Zimbabwe; Karl Technau, Rahima Moosa Mother and Child Hospital, South Africa; Brian
Eley, Red Cross Children’s Hospital, South Africa; Josephine Muhairwe, SolidarMed
Lesotho; Anna Jores, SolidarMed Mozambique; Cordelia Kunzekwenyika, SolidarMed
Zimbabwe, Matthew P Fox, Themba Lethu Clinic, South Africa; Hans Prozesky, Tygerberg
Academic Hospital, South Africa.
Author Contributions
Conceptualization: Gabriela Patten, Jonathan Bernheimer, Mary-Ann Davies.
Data curation: Gabriela Patten, Shobna Sawry.
Formal analysis: Gabriela Patten, Lee Fairlie, Helena Rabie, Karl Technau, Brian Eley, Mary-
Ann Davies.
Investigation: Lee Fairlie.
Methodology: Gabriela Patten, Lee Fairlie.
Project administration: Gabriela Patten.
Supervision: Mary-Ann Davies.
Visualization: Gabriela Patten.
Writing – original draft: Gabriela Patten, Lee Fairlie.
Writing – review & editing: Jonathan Bernheimer, Lee Fairlie, Helena Rabie, Shobna Sawry,
Karl Technau, Brian Eley, Mary-Ann Davies.
References
1. Davies MA, Moultrie H, Eley B, Rabie H, Van Cutsem G, Giddy J, et al. Virologic failure and second-line
antiretroviral therapy in children in South Africa—the IeDEA Southern Africa collaboration. J Acquir
Immune Defic Syndr. 2011; 56(3):270–8. https://doi.org/10.1097/QAI.0b013e3182060610 PMID:
21107266
2. Meyers T, Moultrie H, Naidoo K, Cotton M, Eley B, Sherman G. Challenges to pediatric HIV care and
treatment in South Africa. J Infect Dis. 2007; 196 Suppl 3:S474–81. https://doi.org/10.1086/521116
PMID: 18181697
3. Steele RG, Nelson TD, Cole BP. Psychosocial functioning of children with AIDS and HIV infection:
review of the literature from a socioecological framework. J Dev Behav Pediatr. 2007; 28(1):58–69.
https://doi.org/10.1097/DBP.0b013e31803084c6 PMID: 17353739
4. Agwu AL, Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-
infected adolescents. J Int AIDS Soc. 2013; 16:18579. https://doi.org/10.7448/IAS.16.1.18579 PMID:
23782477
5. Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2009; 6
(4):194–200. PMID: 19849962
6. National Consolidatd Guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and
the management of HIV in children, adolescents and adults. National Department of Health, South
Africa, 2015.
7. Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, et al. Mechanistic basis for reduced
viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.
J Biol Chem. 2004; 279(1):509–16. https://doi.org/10.1074/jbc.M308806200 PMID: 14551187
8. Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, et al. Prior therapy influences the efficacy
of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. J Acquir Immune Defic
Syndr. 2010; 54(1):51–8. https://doi.org/10.1097/QAI.0b013e3181bef889 PMID: 19838125
Lamivudine monotherapy in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0205455 October 11, 2018 11 / 12
9. Gianotti N, Tiberi S, Menzo S, Danise A, Boeri E, Galli L, et al. HIV-1 replication capacity and genotype
changes in patients undergoing treatment interruption or lamivudine monotherapy. Journal Med Virol.
2008; 80(2):201–8. https://doi.org/10.1002/jmv.21085 PMID: 18098142
10. Quan Y, Brenner BG, Oliveira M, Wainberg MA. Lamivudine can exert a modest antiviral effect against
human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother.
2003; 47(2):747–54. https://doi.org/10.1128/AAC.47.2.747-754.2003 PMID: 12543687
11. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV-1-
infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).
AIDS. 2006; 20(6):795–803. https://doi.org/10.1097/01.aids.0000218542.08845.b2 PMID: 16549962
12. Devereux HL, Emery VC, Johnson MA, Loveday C. Replicative fitness in vivo of HIV-1 variants with
multiple drug resistance-associated mutations. J Med Virol. 2001; 65(2):218–24. PMID: 11536226
13. Soria A, Danise A, Galli L, Tiberi S, Seminari E, Cossarini F, et al. Viro-immunological dynamics in HIV-
1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot
randomised trial. J Clin Virol. 2010; 47(3):253–7. https://doi.org/10.1016/j.jcv.2009.12.007 PMID:
20056480
14. Lazarus EM OK, Fairlie L, Untiedt S, Violari A, Laher F, Evans D, Levin L. Lamivudine Monotherapy as
a Holding Strategy in HIV-Infected Children in South Africa. J AIDS Clin Res. 4(10).
15. Linder V, Goldswain C, Adler H, Carty C, Harper K, Jackson V, et al. Lamivudine Monotherapy: Experi-
ence of Medium-term Outcomes in HIV-infected Children Unable to Adhere to Triple Therapy. Pediatr
Infect Dis J. 2016; 35(7):e199–205. https://doi.org/10.1097/INF.0000000000001156 PMID: 27031256
16. Linder V, Goldswain C, Boon G, Carty C, Jackson V, Harper K, et al. Lamivudine monotherapy as a
safe option for HIV-infected paediatric clients with adherence challenges: new evidence from a large
South African cohort. J Int AIDS Soc. 2014; 17(4 Suppl 3):19763. https://doi.org/10.7448/ias.17.4.
19763 PMID: 25397507
17. Rabie H, Essack G, Cotton M, editors. Monotherapy with lamivudine in HIV-infected children: the expe-
rience at Tygerberg hospital. South African HIV Clinicians Society Conference; 2012 25–28 November
2012; Cape Town, South Africa.
18. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort Profile: the inter-
national epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol.
2012; 41(5):1256–64. https://doi.org/10.1093/ije/dyr080 PMID: 21593078
19. National Antiretroviral Treatment Guidelines. In: National Department of Health SA, editor.: Jacana;
2004.
20. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al. Effect of rifampicin on lopinavir phar-
macokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008; 47(5):566–
9. https://doi.org/10.1097/QAI.0b013e3181642257 PMID: 18197120
21. Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, et al. Pharmacokinetics,
safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS.
2008; 22(2):249–55. https://doi.org/10.1097/QAD.0b013e3282f2be1d PMID: 18097227
22. WHO. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Switzer-
land: 2006.
23. Rakhmanina N, Lam KS, Hern J, Young HA, Walters A, Castel AD. Interruptions of antiretroviral therapy
in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the
USA. J Int AIDS Soc. 2016; 19(1):20936. https://doi.org/10.7448/IAS.19.1.20936 PMID: 27797320
24. Agwu A, Warshaw M, Siberry GK, Melvin A, McFarland E, Wiznia A editors. 3TC/FTC monotherapy vs.
continuing failing cART as a bridging ART strategy in persistently nonadherent HIV-infected youth with
M184V resistance: results of IMPAACT P1094. 6th International Workshop on HIV Pediatrics; 2014;
Melbourne, Australia.
25. Fairlie L, Karalius B, Patel K, van Dyke RB, Hazra R, Hernan MA, et al. CD4+ and viral load outcomes
of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in
perinatally HIV-infected youth in the United States. AIDS. 2015; 29(16):2109–19. https://doi.org/10.
1097/QAD.0000000000000809 PMID: 26182197
26. Lazarus E, Nicol S, Frigati L, Penazzato M, Cotton MF, Centeno-Tablante E, et al. Second- and Third-
line Antiretroviral Therapy for Children and Adolescents: A Scoping Review. Pediatr Infect Dis J. 2017;
36(5):492–9. https://doi.org/10.1097/INF.0000000000001481 PMID: 28403052
Lamivudine monotherapy in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0205455 October 11, 2018 12 / 12
